



Maximilian Julve

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

900 Blake Wilbur Dr 3rd Fl

3rd Fl

Stanford, CA 94305

Tel (650) 724-9707

Fax (650) 724-1445

Bio

BIO

Dr. Max Julve is a medical oncologist and Clinical Assistant Professor of Medicine (Oncology) at Stanford University School of Medicine, with a clinical and research focus in solid tumor cellular therapy and melanoma.

Dr. Julve completed his medical training at Barts and The Royal London School of Medicine in the United Kingdom, followed by internal medicine training at teaching hospitals across North and Central London. He was subsequently awarded a National Institute for Health and Care Research (NIHR) Academic Clinical Fellowship in Medical Oncology at Imperial College London. During this time, alongside his clinical training, he conducted translational research within the King's College London Immunoengineering group, focusing on transcriptional optimization of CAR-T cell therapies.

Dr. Julve later completed advanced clinical fellowships in solid tumor cellular therapy and melanoma at The Royal Marsden Hospital, London, and earned an MD(Res) doctorate investigating the role of immunosuppressive granulocytes in patients receiving immunotherapy.

He is a clinical investigator specializing in melanoma, immuno-oncology, and solid tumor cellular therapy, with a particular emphasis on translating mechanistic insights from the laboratory into novel therapeutic strategies for patients.

CLINICAL FOCUS

- Melanoma
- Cellular therapy
- Novel immunotherapies
- Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- MRCP (UK), The Royal College of Physicians (2022 - present)
- ESMO-ACP(UK) Ambassador, ESMO (2023 - 2025)

PROFESSIONAL EDUCATION

- Board Certification: Oncology, General Medical Council (2025)
- Fellowship: Royal Marsden Hospital (2025) England
- Fellowship: Royal Marsden Hospital (2024) England
- Fellowship: Imperial College, School of Medicine (2021) UK
- Residency: Imperial College, School of Medicine (2017) UK
- Internship: Royal Free Hospital School of Medicine (2015) UK
- Medical Education: Queen Mary University of London (2013) United Kingdom
- MD(Res), The Institute of Cancer Research , Translational Immunotherapy (2025)
- CCT (UK Specialty Training), General Medical Council (United Kingdom) , Medical Oncology (2025)
- Postgraduate Diploma, The Institute of Cancer Research, London , Oncology (2022)
- MBBS, Bart's and The Royal London School of Medicine , Medicine (2013)
- BSc(hons), University of Bristol , Biochemistry (2008)

Publications

PUBLICATIONS

- **A novel granulocyte scoring system for use as a predictive/ prognostic biomarker in patients with renal cell carcinoma (RCC) undergoing treatment with combination immunotherapy**
Wong, S. N., Julve, M., Charfare, F., Khatib, K., Cheruvu, S., Le, H. L., Larkin, J., Furness, A.
ELSEVIER.2025
- **Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscape.** *Cancer communications (London, England)*
Thomas, J., Julve, M., Larkin, J., Furness, A.
2025; 45 (11): 1579-1582
- **Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Grover, P., Lo, S. N., Li, I., Kuijpers, A. M., Kreidieh, F., Williamson, A., Amaral, T., Dimitriou, F., Placzke, J., Olino, K., Vitale, M. G., Saiag, P., Gutzmer, et al
2025; 36 (7): 807-818
- **Solid tumour cellular therapy - principles of toxicity management.** *Immuno-oncology technology*
Julve, M., Wong, Y. N., Lim, K. H., Furness, A. J.
2025; 25: 100737
- **Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy**
Julve, M., Wong, Y., Riobo, M., Garitaonandia, Y., Rosero, D. I., Needham, J., Soto, J., Beland, C., Ha Mo Linh Le, Larkin, J., Furness, A. J. S.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Lifileucel: the first cellular therapy approved for solid tumours.** *Trends in cancer*
Julve, M., Lythgoe, M. P., Larkin, J., Furness, A. J.
2024; 10 (6): 475-477
- **Gene of the month: cancer testis antigen gene 1b (NY-ESO-1).** *Journal of clinical pathology*
Julve, M., Kennedy, O., Frampton, A. E., Bagwan, I., Lythgoe, M. P.

2023; 77 (1): 1-7

- **Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma.** *Expert opinion on biological therapy*
Julve, M., Furness, A. J.
2023; 23 (4): 319-323
- **United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review**
Julve, M., Kennedy, O., Lindsay, C., Walters-Davies, R., Button, M. R., Steele, N., McGeogh, A., Georgiou, A., Goranov, B., Farrugia, D., Gorf, L., Remer, M., Shah, et al
ELSEVIER.2022: S1061-S1062
- **Immunotherapy of sarcomas with modified T cells.** *Current opinion in oncology*
Mahalingam, P., Julve, M., Huang, P., Furness, A. J., Pollack, S. M., Jones, R. L.
2022; 34 (4): 362-370
- **Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021.** *BJU international*
Glover, M., Hui, G., Chiang, R., Savage, P., Krell, J., Julve, M., Grivas, P., Lythgoe, M., Khaki, A. R.
2021
- **Pleomorphic lung carcinoma - a rare response to a rare tumour**
Clark, J., Murphy, R., Dell, E., Julve, M., Januszewski, A., Popat, S., Newsom-Davis, T.
ELSEVIER IRELAND LTD.2021: S76
- **Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma.** *Expert opinion on pharmacotherapy*
Julve, M., Clark, J. J., Lythgoe, M. P.
2021; 22 (3): 351-361
- **Rare case of adult pancreatoblastoma.** *BMJ case reports*
Morrisey, G., Cohen, P., Julve, M.
2020; 13 (4)
- **Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Spain, L., Walls, G., Julve, M., O'Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J., Larkin, J.
2017; 28 (2): 377-385
- **Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.** *Expert opinion on pharmacotherapy*
Spain, L., Julve, M., Larkin, J.
2016; 17 (7): 1031-8
- **Bilateral extraocular muscle (EOM) metastases from adenocarcinoma of the gastro-oesophageal junction (GOJ).** *BMJ case reports*
Julve, M., Maviki, M., Gillmore, R.
2014; 2014